Heterologous vaccination utilizing viral vector and protein platforms confers complete protection against SFTSV

Jae Yong Kim; Kyeongseok Jeon; Jung Joo Hong; Sang In Park; Hyeonggon Cho; Hyo Jung Park; Hye Won Kwak; Hyeong Jun Park; Yoo Jin Bang; Yu Sun Lee; Seo Hyeon Bae; So Hee Kim; Kyung Ah Hwang; Dae Im Jung; Seong Hoo Cho; Sang Hwan Seo; Green Kim; Hanseul Oh; Hwal Yong Lee; Ki Hyun Kim; Hee Young Lim; Pyeonghwa Jeon; Joo Yeon Lee; Junho Chung; Sang Myeong Lee; Hae Li Ko; Manki Song; Nam Hyuk Cho; Young suk Lee; So Hee Hong; Jae Hwan Nam

doi:10.1038/s41598-023-35328-9

Heterologous vaccination utilizing viral vector and protein platforms confers complete protection against SFTSV

Jae Yong Kim, Kyeongseok Jeon, Jung Joo Hong, Sang In Park, Hyeonggon Cho, Hyo Jung Park, Hye Won Kwak, Hyeong Jun Park, Yoo Jin Bang, Yu Sun Lee, Seo Hyeon Bae, So Hee Kim, Kyung Ah Hwang, Dae Im Jung, Seong Hoo Cho, Sang Hwan Seo, Green Kim, Hanseul Oh, Hwal Yong Lee, Ki Hyun KimHee Young Lim, Pyeonghwa Jeon, Joo Yeon Lee, Junho Chung, Sang Myeong Lee, Hae Li Ko, Manki Song, Nam Hyuk Cho, Young suk Lee, So Hee Hong, Jae Hwan Nam

Department of Microbiology

Research output: Contribution to journal › Article › peer-review

Abstract

Severe fever with thrombocytopenia syndrome virus was first discovered in 2009 as the causative agent of severe fever with thrombocytopenia syndrome. Despite its potential threat to public health, no prophylactic vaccine is yet available. This study developed a heterologous prime-boost strategy comprising priming with recombinant replication-deficient human adenovirus type 5 (rAd5) expressing the surface glycoprotein, Gn, and boosting with Gn protein. This vaccination regimen induced balanced Th1/Th2 immune responses and resulted in potent humoral and T cell-mediated responses in mice. It elicited high neutralizing antibody titers in both mice and non-human primates. Transcriptome analysis revealed that rAd5 and Gn proteins induced adaptive and innate immune pathways, respectively. This study provides immunological and mechanistic insight into this heterologous regimen and paves the way for future strategies against emerging infectious diseases.

Original language	English
Article number	8189
Journal	Scientific Reports
Volume	13
Issue number	1
DOIs	https://doi.org/10.1038/s41598-023-35328-9
State	Published - Dec 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41598-023-35328-9

Cite this

Kim, J. Y., Jeon, K., Hong, J. J., Park, S. I., Cho, H., Park, H. J., Kwak, H. W., Park, H. J., Bang, Y. J., Lee, Y. S., Bae, S. H., Kim, S. H., Hwang, K. A., Jung, D. I., Cho, S. H., Seo, S. H., Kim, G., Oh, H., Lee, H. Y., ... Nam, J. H. (2023). Heterologous vaccination utilizing viral vector and protein platforms confers complete protection against SFTSV. Scientific Reports, 13(1), Article 8189. https://doi.org/10.1038/s41598-023-35328-9

@article{1c8538e674c546c1940d3fd37d376997,

title = "Heterologous vaccination utilizing viral vector and protein platforms confers complete protection against SFTSV",

abstract = "Severe fever with thrombocytopenia syndrome virus was first discovered in 2009 as the causative agent of severe fever with thrombocytopenia syndrome. Despite its potential threat to public health, no prophylactic vaccine is yet available. This study developed a heterologous prime-boost strategy comprising priming with recombinant replication-deficient human adenovirus type 5 (rAd5) expressing the surface glycoprotein, Gn, and boosting with Gn protein. This vaccination regimen induced balanced Th1/Th2 immune responses and resulted in potent humoral and T cell-mediated responses in mice. It elicited high neutralizing antibody titers in both mice and non-human primates. Transcriptome analysis revealed that rAd5 and Gn proteins induced adaptive and innate immune pathways, respectively. This study provides immunological and mechanistic insight into this heterologous regimen and paves the way for future strategies against emerging infectious diseases.",

author = "Kim, {Jae Yong} and Kyeongseok Jeon and Hong, {Jung Joo} and Park, {Sang In} and Hyeonggon Cho and Park, {Hyo Jung} and Kwak, {Hye Won} and Park, {Hyeong Jun} and Bang, {Yoo Jin} and Lee, {Yu Sun} and Bae, {Seo Hyeon} and Kim, {So Hee} and Hwang, {Kyung Ah} and Jung, {Dae Im} and Cho, {Seong Hoo} and Seo, {Sang Hwan} and Green Kim and Hanseul Oh and Lee, {Hwal Yong} and Kim, {Ki Hyun} and Lim, {Hee Young} and Pyeonghwa Jeon and Lee, {Joo Yeon} and Junho Chung and Lee, {Sang Myeong} and Ko, {Hae Li} and Manki Song and Cho, {Nam Hyuk} and Lee, {Young suk} and Hong, {So Hee} and Nam, {Jae Hwan}",

note = "Funding Information: J-H. N was supported by funding from the Research Unit of Korea Center for Disease Control and Prevention (Grant Numbers 2020-ER5303-00 and 2022-NI-045-00). J J.H. was supported by the Korea Research Institute of Bioscience and Biotechnology Research Initiative Programs (Grant Number KGM 4572121). S-H.H was supported by the Bio and medical technology development program of the National Research Foundation of Korea (NRF) Grant funded by the Korean government (Grant Number 2022M3E5F1016595). H-J. Park was supported by a grant from the Ministry of Food and Drug Safety in 2022 (Grant Number 22203MFDS404). Publisher Copyright: {\textcopyright} 2023, The Author(s).",

year = "2023",

month = dec,

doi = "10.1038/s41598-023-35328-9",

language = "English",

volume = "13",

journal = "Scientific Reports",

issn = "2045-2322",

publisher = "Nature Publishing Group",

number = "1",

}

Kim, JY, Jeon, K, Hong, JJ, Park, SI, Cho, H, Park, HJ, Kwak, HW, Park, HJ, Bang, YJ, Lee, YS, Bae, SH, Kim, SH, Hwang, KA, Jung, DI, Cho, SH, Seo, SH, Kim, G, Oh, H, Lee, HY, Kim, KH, Lim, HY, Jeon, P, Lee, JY, Chung, J, Lee, SM, Ko, HL, Song, M, Cho, NH, Lee, YS, Hong, SH & Nam, JH 2023, 'Heterologous vaccination utilizing viral vector and protein platforms confers complete protection against SFTSV', Scientific Reports, vol. 13, no. 1, 8189. https://doi.org/10.1038/s41598-023-35328-9

TY - JOUR

T1 - Heterologous vaccination utilizing viral vector and protein platforms confers complete protection against SFTSV

AU - Kim, Jae Yong

AU - Jeon, Kyeongseok

AU - Hong, Jung Joo

AU - Park, Sang In

AU - Cho, Hyeonggon

AU - Park, Hyo Jung

AU - Kwak, Hye Won

AU - Park, Hyeong Jun

AU - Bang, Yoo Jin

AU - Lee, Yu Sun

AU - Bae, Seo Hyeon

AU - Kim, So Hee

AU - Hwang, Kyung Ah

AU - Jung, Dae Im

AU - Cho, Seong Hoo

AU - Seo, Sang Hwan

AU - Kim, Green

AU - Oh, Hanseul

AU - Lee, Hwal Yong

AU - Kim, Ki Hyun

AU - Lim, Hee Young

AU - Jeon, Pyeonghwa

AU - Lee, Joo Yeon

AU - Chung, Junho

AU - Lee, Sang Myeong

AU - Ko, Hae Li

AU - Song, Manki

AU - Cho, Nam Hyuk

AU - Lee, Young suk

AU - Hong, So Hee

AU - Nam, Jae Hwan

N1 - Funding Information: J-H. N was supported by funding from the Research Unit of Korea Center for Disease Control and Prevention (Grant Numbers 2020-ER5303-00 and 2022-NI-045-00). J J.H. was supported by the Korea Research Institute of Bioscience and Biotechnology Research Initiative Programs (Grant Number KGM 4572121). S-H.H was supported by the Bio and medical technology development program of the National Research Foundation of Korea (NRF) Grant funded by the Korean government (Grant Number 2022M3E5F1016595). H-J. Park was supported by a grant from the Ministry of Food and Drug Safety in 2022 (Grant Number 22203MFDS404). Publisher Copyright: © 2023, The Author(s).

PY - 2023/12

Y1 - 2023/12

N2 - Severe fever with thrombocytopenia syndrome virus was first discovered in 2009 as the causative agent of severe fever with thrombocytopenia syndrome. Despite its potential threat to public health, no prophylactic vaccine is yet available. This study developed a heterologous prime-boost strategy comprising priming with recombinant replication-deficient human adenovirus type 5 (rAd5) expressing the surface glycoprotein, Gn, and boosting with Gn protein. This vaccination regimen induced balanced Th1/Th2 immune responses and resulted in potent humoral and T cell-mediated responses in mice. It elicited high neutralizing antibody titers in both mice and non-human primates. Transcriptome analysis revealed that rAd5 and Gn proteins induced adaptive and innate immune pathways, respectively. This study provides immunological and mechanistic insight into this heterologous regimen and paves the way for future strategies against emerging infectious diseases.

AB - Severe fever with thrombocytopenia syndrome virus was first discovered in 2009 as the causative agent of severe fever with thrombocytopenia syndrome. Despite its potential threat to public health, no prophylactic vaccine is yet available. This study developed a heterologous prime-boost strategy comprising priming with recombinant replication-deficient human adenovirus type 5 (rAd5) expressing the surface glycoprotein, Gn, and boosting with Gn protein. This vaccination regimen induced balanced Th1/Th2 immune responses and resulted in potent humoral and T cell-mediated responses in mice. It elicited high neutralizing antibody titers in both mice and non-human primates. Transcriptome analysis revealed that rAd5 and Gn proteins induced adaptive and innate immune pathways, respectively. This study provides immunological and mechanistic insight into this heterologous regimen and paves the way for future strategies against emerging infectious diseases.

UR - http://www.scopus.com/inward/record.url?scp=85159675820&partnerID=8YFLogxK

U2 - 10.1038/s41598-023-35328-9

DO - 10.1038/s41598-023-35328-9

M3 - Article

C2 - 37210393

AN - SCOPUS:85159675820

SN - 2045-2322

VL - 13

JO - Scientific Reports

JF - Scientific Reports

IS - 1

M1 - 8189

ER -

Heterologous vaccination utilizing viral vector and protein platforms confers complete protection against SFTSV

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this